Home > Boards > US OTC > Medical - Equipment > GeneSYS ID Inc. (GNID)

Chief Counsel, CSO...GNID Mark Basile = LOSER

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
MDRESEARCH Member Profile
Followed By 53
Posts 11,598
Boards Moderated 0
Alias Born 11/26/14
160x600 placeholder
MDRESEARCH   Monday, 02/05/18 07:48:33 PM
Re: None
Post # of 32391 
Chief Counsel, CSO...GNID Mark Basile = LOSER

December 19, 2017
Lorraine Yarde
Chief Executive Officer
GeneSYS ID, Inc.
171 Green Valley Parkway, Suite 300
Henderson, NV 89012
Re: GeneSYS ID, Inc.
Form 10-K for Fiscal Year Ended December 31, 2015
Filed March 28, 2016
Form 10-Q for Fiscal Quarter Ended September 30, 2016
Filed November 21, 2016
File No. 000-55373
Dear Ms. Yarde:
We issued comments on the above captioned filings on February 3, 2017. On June 1,
2017, we issued an oral comment informing you that a comment remained outstanding and
unresolved, and absent a substantive response, we would act consistent with our obligations
under the federal securities laws.
As you have not provided a substantive response, we are terminating our review and will
take further steps as we deem appropriate. These steps include releasing publicly, through the
agency’s EDGAR system, all correspondence, including this letter, relating to the review of your
filings, consistent with the staff’s decision to publicly release comment and response letters

relating to disclosure filings it has reviewed.
Please contact Christie Wong, Staff Accountant, at (202) 551-3684 or Carlos Pacho,
Senior Assistant Chief Accountant, at (202) 551-3835 with any other questions.
/s/ Robert S. Littlepage

The Problem: FAILURE by a CEO in PENNYLAND, is not only an Acceptable Practice, it REWARDS a CEO... It's much EASIER for CEO to make money selling Company shares, than Build a Company.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist